– Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)
– Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing
– U.S.-based Bio-Techne to bring…

– Connects physical products directly to digital workflows to reduce manual steps and boost efficiency
– Enables instant access to product documentation such as safety data sheets (SDS) and certificates of analysis (CoA)
– Built on the Merck M-Trust™ platform for secure and traceable laboratory proces…

– Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilience
– Merck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricity
– New Blarney site in Cork, Ireland expands filter manufacturing capacity, creating mo…

– Partnership aims at developing next-generation microphysiological systems (MPS)-on-a-chip through multipartner collaboration program
– Modular, scalable MPS platform envisions unprecedented accuracy in simulating human body responses, providing reliable and high-quality training data for AI models
…

– Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharma
– Meets growing need for autonomous tools that boost throughput and reproducibility
– Provides customers with verified and automated workflows

Merck, a leading science and technology com…

– Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development
– HUB’s organoid offering complements company’s cell culture portfolio of media, reagents, and benchtop instrumentation
– Organoids provide drug response data earlier in the development…

– Following the announcement of the multidisciplinary research program last year, the selection process for funded projects has been completed
– Six projects involving eleven scientific institutions from six European countries are supported by Merck and Intel
– The focus is on the application of Artif…

– Acquisition will advance Merck’s integrated offering for viral vector manufacturing
– Complements existing portfolio for development and production of novel modalities such as cell and gene therapies
– Novel modalities are a key growth area for Merck’s Life Science business sector

Merck, a leading sc…

– German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony
– Research center to accelerate biopharmaceutical product development
– Part of Merck’s € 1.5 billion investment program in Darmstadt by 2025

Merck, a leading science and technology c…

– Site to supply products to customers for development and production of biologics
– New Bioprocessing Production Center in Daejeon strengthens footprint of Merck in fast-growing Asia-Pacific region
– Investment to create up to 300 additional jobs

Merck invests more than € 300 million into a new Biopro…